StimuSIL Funding & Investors
StimuSIL is a medical device company in the process of developing new technologies for safer and more effective photobiomodulation (PBM) therapy, with the goal of targeting multiple indications in dermatology and aesthetics. StimuSIL’s proprietary technologies aim to deliver PBM across the melanin layer of the skin in order to enhance this treatment’s biostimulatory effects. StimuSIL was established in January 2020 in Washington, D.C. by Pablo Villalba Villar.
stimusil.comTotal Amount Raised: $1,727,584
StimuSIL Funding Rounds
Series Unknown
$1,103,787
Seed
$48,799
Seed
$574,998
Funding info provided by Diffbot.